Helen Mclean

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

A. Borodovsky, N. Najafian, Jae B. Kim, 2016 .

Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Crows Feet Lines: A Multicenter, Randomized, Controlled Trial

S. Cox, A. Carruthers, S. Bruce, 2014, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].